Ira J Fox

US Patent:

20220362405, Nov 17, 2022

Filed:

Oct 14, 2020

Appl. No.:

17/769886

Inventors:

- Pittsburgh PA, US
Aaron Bell - West Mifflin PA, US
Nicolas Fraunhoffer Navarro - Pittsburgh PA, US
Jorge Guzman Lepe - Pittsburgh PA, US
Sarah Hainer - Pittsburgh PA, US
George K. Michalopoulos - Pittsburgh PA, US
Alina Ostrowska - Mckees Rocks PA, US
Ira Fox - Pittsburgh PA, US
Edgar Naoe Tafaleng - Pittsburgh PA, US
Kazuki Takeishi - Fukuoka, JP

International Classification:

A61K 48/00
A61P 1/16

Abstract:

Disclosed are compositions and methods for treating a liver disease in a subject by increasing transport or retention of HNF4α, a transcriptional factor, into a nucleus of a hepatocyte in the subject. In some embodiments, the method comprises upregulating expression or function of one or more transcription factors selected from the group consisting of PROX1, NR5A2, NROB2, MTF1, SREBP1, EP300, and POM121C, and functional fragments thereof, and/or downregulating expression or function of one or more transcription factors DNAJB 1/F1SP40, ATF6, ATF4, and PERK, and functional fragments thereof.

US Patent:

20190185819, Jun 20, 2019

Filed:

Jul 31, 2017

Appl. No.:

16/322087

Inventors:

- Pittsburgh PA, US
Alexandra Sylvie Collin de l'Hortet - Pittsburgh PA, US
Kan Handa - Pittsburgh PA, US
Jorge Guzman Lepe - Pittsburgh PA, US
Yang Wang - Pittsburgh PA, US
Kazuki Takeishi - Pittsburgh PA, US
Ira Jacob Fox - Pittsburgh PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C12N 5/074
C12N 15/11
C12N 9/22

Abstract:

Methods are disclosed herein for efficiently generating human induced pluripotent stem cells (iPSC) containing a nucleic acid including a doxycycline promoter operably linked to a nucleic acid encoding Cas9. These methods include transfecting a human somatic cell with a nucleic acid molecule comprising a doxycycline promoter operably linked to a nucleic acid encoding a Cas9, and constitutive promoter operably linked to a tetracycline responsive element and inducing the somatic cell to form an iPSC, thereby producing an iPSC that can undergo CRISPR/Cas9-mediated recombination at a high efficiency. The human iPSC, or a cell differentiated therefrom, is cultured in the presence of doxycycline to induce expression of the Cas9. These cells can then be used to target in any gene of interest by introducing nucleic acids encoding sgRNAs. Induced pluripotent stem cells produced by these methods are also disclosed.

US Patent:

20070264243, Nov 15, 2007

Filed:

Apr 23, 2007

Appl. No.:

11/738678

Inventors:

Ira Fox - Omaha NE, US
Philippe LeBoulch - Charleston MA, US
Naoya Kobayashi - Okayama, JP

International Classification:

A61K 48/00
A61K 39/00
A61P 1/16
C12N 5/08

US Classification:

424093210, 435370000, 435455000

Abstract:

Hepatocyte cells that are reversibly immortalized and grown in culture, which are functional and safe for use in transplantation, are disclosed. Also disclosed are methods for immortalizing primary hepatocytes, expanding the population of immortalized hepatocytes in culture, then reversing the immortalization to produce hepatocytes that are functional and safe for use in transplantation.